Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: A retrospective cohort study

European Journal of Dermatology

Volumn 21, Issue 6, 2011, Pages 916-920

  Lestre, Sara ^a   Diamantino, Filipa ^a   Veloso, Luis ^b   Fidalgo, Ana ^a   Ferreira, Ana ^a  

^a HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

^b Eurotrials Scientific Consultants   (Portugal)

Author keywords

Cardiovascular disease; Etanercept; Lipid profile; Metabolic syndrome; Psoriasis; Tumor necrosis factor alpha inhibitors

Indexed keywords

BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CHOLESTEROL; CYCLOSPORIN; ETANERCEPT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; RETINOID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; MEDICAL RECORD; MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS; OBESITY; PHOTOTHERAPY; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHRONIC DISEASE; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; LIPIDS; MALE; MIDDLE AGED; OVERWEIGHT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855984898     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1548     Document Type: Article

References (29)

1. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
2. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19: 5-21.
3. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am Heart J 2005; 149: 33-45.
4. Bernstein L, Berry J, Kim S. Effects of Etanercept in Patients with the Metabolic Syndrome. Arch Intern Med 2006; 166: 902-8.
5. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practise Research Database. Eur Heart J 2010; 31: 1000-6.
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
7. Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-9.
8. Jamnistki A, Visman IM, Peters MJL, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010; 69: 1929-33.
9. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 414-9.
10. Seriolo B, Paolino S, Ferrone C, et al. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis. Clin Rheumatol 2007; 26: 1799-800.
11. Popa C, Netea MG, Radstake T, et al. Influence of anti tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-5.
12. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-355.
13. Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006; 365: 143-8.
14. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006; 33: 2440-6.
15. van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in highdensity lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1324-30.
16. Garcês SP, Parreira Santos MJ, Vinagre FMR, et al. Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann Rheum Dis 2008; 67: 895-6.
17. Schreyer SA, Vick CM, LaBoeuf RC. Loss of lymphotoxin-alfa but not tumor necrosis factor - alfa reduces atherosclerosis in mice. J Biol Chem 2002; 277: 12364-8.
18. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-6.
19. Martínez-Abundis E, Reynoso-von DC, Hernández-Salazar E, et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461-5.
20. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis-alpha on body mass index in patients with psoriasis. Pharmacol Res 2008: 90-5.
21. Gisondi P, Cotena C, Tessari G, Girolomoni GJ. Anti-tumor necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort-study. J Eur Acad Dermatol Venereol. 2008; 22: 341-4.
22. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75: 22-4.
23. Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010; 77: 50-2.
24. Channual J, Wu JJ, Dann F. Effects of tumor necrosis factor-_blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther 2009; 22: 61-73.
25. Vena GA, Vestita M, Cassano N. Can early treatment with biological modify the natural history of comorbidities? Dermatol Ther 2010; 23: 181-93.
26. Vena AG, Altomare G, Avala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care data base. Eur J Dermatol 2010; 20: 593-8.
27. Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and Psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63: 1058-69.
28. Carmo I, Santos O, Camolas J, et al. Prevalence of obesity in Portugal. Obes Rev 2006; 7: 233-7.
29. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30.